

BTOG 2019 Programme

Continuing Professional Development – CPD – Accredited by

The Royal College of Pathologists for 13 CPD Credits

RCSI Faculty of Radiologists for 13.5 CPD Credits (Accepted by all Irish Postgraduate Medical Training Bodies)

The Royal College of Surgeons of England for up to 16.5 CPD points

Accreditation applied for from

The Federation of the Royal Colleges of Physicians of the United Kingdom

Conflict of Interest Declarations

Speakers will declare nil or any conflict of interest on the 1st slide of their presentation.

Chairs will declare nil or any conflict of interest during their introductions.

Wednesday 23rd January 2019

10:00 Registration Opens & Refreshments

The BTOG Desk is available for registration/information throughout BTOG 2019.

Ground Floor
Conference Foyer

11:00 – 14:30 BTOG Parallel Symposia (4)

BTOG Translational Oncology Symposium

Herbert

20 minutes + 10 minutes discussion per speaker

Session 1

Chairs: Rolf Stahel (CH) and Samreen Ahmed (UK)

11:00 Tumour mutation burden for thoracic tumours: importance and implications

Gary Middleton (UK)

11:30 Can DNA repair be exploited?

Ken O'Byrne (AU)

12:00 Cancer whole genome sequencing: the GEL legacy

Nirupa Murugaesu (UK)

12:30 – 13:00 Lunch and Exhibition

Ground Floor
Conference Foyer

Session 2

Chairs: Denis Talbot (UK) and Alastair Greystoke (UK)

13:00 TKI resistance: lessons learned from ALK

Ross Camidge (US)

13:30 Adoptive cell therapy for solid tumours: what you need to know

Sophie Papa (UK)

14:00 Targeting KRAS: hopeless or hopeful?

Udai Banerji (UK)

14:30 – 15:00 Refreshments and Exhibition

Ground Floor
Conference Foyer

Wednesday 23rd January 2019

BTOG Radiotherapy Symposium

Pembroke

Session 1 Stage III NSCLC Update

Chairs: Stephen Harrow (UK) and Matthew Hatton (UK)

11:00	National Data on Management of Stage III NSCLC	Susan Harden (UK)
11:15	Technology matters	Alan McWilliam (UK)
11:30	Questions and discussion	
11:45	Patient selection & systemic therapy update	Jason Lester (UK)
12:00	Immuno-Toxicity: lessons learnt from advanced disease (UK)	Tom Newsom-Davis
12:15	Questions and discussion	

12:30 – 13:00 Lunch and Exhibition

**Ground Floor
Conference Foyer**

Session 2 Stereotactic Radiotherapy Update

Chairs: Clive Peedell (UK) and Kevin Franks (UK)

13:00	Synchronous, metachronous oligometastatic & oligoprogressive NSCLC: Current data	Alexander Louie (CA)
13:30	Early stage disease: Optimal approach with central / ultracentral lesions	John Conibear (UK) Iain Phillips (UK)
14:00	National Data on Management of Early Stage Disease	
14:10	Questions and discussion	

14:30 – 15:00 Refreshments and Exhibition

**Ground Floor
Conference Foyer**

BTOG Diagnostic Symposium

Fitzwilliam

20 minutes + 10 minutes discussion per speaker

Session 1 The Optimal Supportive Care Pathway

Chairs: Karen Clayton (UK) and Vidan Masani (UK)

11:00	Practical Delivery of Enhanced Recovery	Babu Naidu (UK)
11:30	Getting Ready for Treatment - Supportive Care Perspective	Barry Laird (UK)
12:00	Managing Tobacco Addiction in the Optimal Pathway	Matthew Evison (UK)

12:30 – 13:00 Lunch and Exhibition

**Ground Floor
Conference Foyer**

Session 2 Practical Implementation of LDCT Screening

Chairs: David Baldwin (UK) and Sam Janes (UK)

13:00	Significant Incidental Findings: Harm or Benefit and What to Do	Richard Booton (UK)
13:30	Nodule Management: BTS vs Fleischner & the role of Volumetry, CAD and AI	Fergus Gleeson (UK)
14:00	Upskilling the Workforce: Image-guided Biopsy of Subcentimetre Nodules	Anna Sharman (UK)

14:30 – 15:00 Refreshments and Exhibition

**Ground Floor
Conference Foyer**

Wednesday 23rd January 2019

**Association of Pulmonary Pathologists
APP/BTOG Symposium**

Meeting Room 6, 1st Floor

20 minutes + 10 minutes discussion per speaker

Session 1: Lung Cancer Diagnostics in 2020; the View from Pathology

Chair: Emily Shaw (UK)

11:00	Detecting the drivers; what, when and how	Matt Evans (UK)
11:30	Protein expression as predictive markers; PD-L1, DLL3 and beyond	Alex Haragan (UK)
12:00	Role of the pathologist in the genomic age; gathering, interpreting and integrating the data	David Moore (UK)

12:30 – 13:00 Lunch and Exhibition

**Ground Floor
Conference Foyer**

Session 2: Case presentations: A Selection of the Weird and the Wonderful

Chairs: Siobhan Nicholson (IE) and Aurelie Fabre (IE)

13:00 6 case presentations – 15 minutes each

14:30 – 15:00 Refreshments and Exhibition

**Ground Floor
Conference Foyer**

14:30 Refreshments & 15:00 – 17:00 BTOG Advocates Meeting

This closed meeting is for advocates only and is not open to all BTOG delegates.

BTOG recognises the importance of input from advocates in improving outcomes for patients and therefore fully funds up to 10 advocates to attend the BTOG annual conference. For this purpose, advocates are patients or patient family members who sit on clinical studies or trial management groups, advisory boards/ groups or other related groups related to lung cancer or mesothelioma.

Meeting Room 9, 1st Floor

15:00 – 19:45 Sponsored Satellite Symposia

45 minutes per satellite symposium

15:00	Satellite symposium sponsored by AstraZeneca	Herbert
16:00	Satellite symposium sponsored by Takeda	
17:00	Satellite symposium sponsored by Roche	
18:00	Satellite symposium sponsored by AstraZeneca	
19:00	Satellite symposium sponsored by MSD	
19:45	Close	

20:00 – 21:30 BTOG Welcome Reception

**Ground Floor
Conference Foyer**

Thursday 24th January 2019

07:30 Registration Opens & Refreshments

The BTOG Desk is available for registration/information throughout BTOG 2019

**Ground Floor
Conference Foyer**

09:00 – 10:50 Session 1

Pembroke/Herbert

09:00	Welcome - BTOG	Sanjay Popat (UK)
09:20	NCRI	Matthew Hatton (UK)
09:30	ETOP	Rolf Stahel (CH)
09:40	EORTC	Anne-Marie Dingemans (NL)
Session 1	Plenary Session	
Chairs:	Michael Peake (UK) and John Field (UK)	
	20 minutes + 10 minutes discussion per speaker	
09:50	NELSON's impact in Europe	Harry De Koning (NL)
10:20	The PACIFIC & beyond: will immunotherapy cure lung cancer?	Martin Reck (DE)

10:50 – 11:20 Refreshments, Exhibition and Posters

**Ground Floor
Conference Foyer**

11:20 – 13:00 Sessions 2 & 3

Session 2

Pembroke/Herbert

Chairs:	John Gosney (UK) and Robert Rintoul (UK)	
	15 minutes + 10 minutes discussion per speaker	
11:20	The CRUK ACE programme: future policy lessons	Sara Hiom (UK)
11:45	Pathology specimens in the immuno-NGS era: quality or quantity?	Keith Kerr (UK)

Session 3 Poster Oral Presentations

Chairs:	Matthew Callister (UK) and Cindy Billingham (UK)	
12:10	Introduction - 7 minutes + 4 minutes discussion per speaker	
12:12	Psychological impact of low-dose CT screening in a 'real world' demonstration lung cancer screening pilot	Sonja Kummer
12:23	Impact of radiographer immediate reporting of chest X-rays from general practice on the lung cancer pathway (radioX)	Nicholas Woznitza
12:34	Modified Lung Immune Predictive Index (mLIPI) as a predictive tool of nivolumab outcomes and immune related adverse events in advanced non-small cell lung cancer (NSCLC) patients	Ken O'Byrne
12:45	PD-L1 expression in resected non-small cell lung cancer; variation between primary tumour and nodal metastases Haragan	Alexander
12:56	Closing comments	
13:00	Close	

Thursday 24th January 2019

13:00 – 14:00 Lunch, Exhibition and Posters

**Ground Floor
Conference Foyer**

13:10 - 13:50 Sponsored Satellite Symposia

13:10 **Satellite symposium sponsored by Pfizer**

Pembroke/Herbert

14:00 – 15:30 Session 4:

Pembroke/Herbert

**Session 4 Multidisciplinary Management of
Thymic Epithelial Malignancies**

Chairs: Alan Kirk (UK) and Louise Burke (IE)

14:00 An introduction to ITMIG
14:05 The surgical approach
14:20 Pathology of thymic epithelial malignancies
14:35 Oncological management
14:50 Pre-op optimization & peri-op care
15:05 Panel and audience discussion

Alan Kirk (UK)
Frank Detterbeck (US)
Andrew Nicholson (UK)
David Gilligan (UK)
Isabel Leite (UK)

15:30 – 16:00 Exhibition and Posters

**Ground Floor
Conference Foyer**

16:00 – 18:00 Collaborative Sessions

Please see next page.

Thursday 24th January 2019

16:00 – 17:00 Parallel Sessions (3)

**BTOG/NCRI LocoRegionalDiagnosis (LORD)
Subgroup Update**

Pembroke

Chair: Mary O'Brien (UK)

16:00 Introduction
How much surgery is necessary for stage I disease?
A neoadjuvant IO study
The non durva stage III patients – what to do?
17:00 Close

Mary O'Brien (UK)
Carol Tan (UK)
Fiona Taylor (UK)
Matthew Evison (UK)

**BTOG/NCRI Mesothelioma
Subgroup Update**

Herbert

Chair: Peter Szlosarek (UK)

16:00 Introduction
16:05 ATOMIC
16:15 MARS2
16:25 MESOTRAP
16:30 CONFIRM
16:35 MIST
16:45 BEAT-meso
16:55 Gaps and new proposals
17:00 Close

Peter Szlosarek (UK)
Peter Szlosarek (UK)
Eric Lim (UK)
Robert Rintoul (UK)
Dean Fennell (UK)
Dean Fennell (UK)
Sanjay Popat (UK)
Peter Szlosarek (UK)

**Association of Pulmonary Pathologists
APP Business Meeting**

Meeting Room 6, 1st Floor

Chairs: John Gosney (UK)

16:00 Open
18:00 Close

17:00 – 18:00 Parallel Sessions (4)

BTOG/NCRI Advanced Disease Subgroup Update

Pembroke

Chair: Fiona Blackhall (UK)

17:00	Overview	Fiona Blackhall (UK)
	PEACE Study Update	David Moore (UK)
	Trials in Development - Audience Participation	Fiona Blackhall (UK)
	TOURIST Trial Overview	David Woolf (UK)
	Brain Metastasis Study Proposal	Simon Page (UK)
18:00	Close	

BTOG/NCRI Screening and Early Diagnosis

Herbert

Subgroup Update - Optimising Lung Cancer Screening

Chair: Neal Navani (UK)

17:00	Improving risk models for participant selection	David Baldwin (UK)
17:20	Understanding patient experiences of screening	Samantha Quaife (UK)
17:40	Integrating biomarkers into screening	Philip Crosbie (UK)
18:00	Close	

BTOG/NLCFN Nursing Session

Meeting Room 1 & 2, 1st Floor

Chairs: Jackie Fenemore (UK) and Angela Tod (UK)

17:00	20 Minutes + 5 minutes discussion	
	Development and evaluation of a self-management intervention for the breathlessness -cough-fatigue symptom cluster in lung cancer	Janelle Yorke (UK)
17:25	7 minutes + 3 minutes discussion per speaker	
	Prospective, multi-centre review to identify readmission rates and causes within 30-days of discharge following primary lung cancer surgery	Maureen King (UK)
	Patient needs regarding the recovery package	Josie Roberts (UK)
	A randomised controlled Trial to Investigate the effectiveness of a nutritional intervention to enhance patient Recovery after elective major lung Surgery-THIRStY Feasibility Study	Amy Kerr (UK)
18:00	Close	

Association of Pulmonary Pathologists

Meeting Room 6, 1st Floor

APP Business Meeting

Chairs: John Gosney (UK)

16:00	Open	18:00	Close
-------	------	-------	-------

19:30 – 20:00 BTOG Reception – Clayton Bar and Reception

Pembroke/Herbert

20:00 – 23:00 17th Annual BTOG 2019 Conference Dinner

Dress code: Gents - lounge suit and tie or black tie / Ladies - cocktail wear

The conference dinner is ticket only and must be pre-booked and includes presentation of the BTOG Lifetime Achievement Award 2019 and poster awards.

Friday 25th January 2019

09:00 – 10:30 Session 5: Lung Cancer Screening in the UK

Pembroke/Herbert

09:00	Roy Castle Lung Cancer Foundation Grants	David Gilligan (UK)
09:05	National Lung Cancer Audit Report	Neal Navani (UK)
09:10	UKLCC Molecules Matter Report	Michael Peake (UK)

Session 5 Implementing Lung Cancer Screening in the UK - if, when and how?

Chairs: Matthew Callister (UK) and Richard Booton (UK)

09:15	The National Screening Committee view post NELSON	Bob Steele (UK)
09:30	Who will read the scans?	Anand Devaraj (UK)
09:45	Who will resect the cancers and how?	Tim Batchelor (UK)
10:00	How do we best integrate smoking cessation?	Rachael Murray (UK)
10:15	Panel and audience discussion	

10:30 – 11:00 Refreshments, Exhibition and Posters

**Ground Floor
Conference Foyer**

11:00 – 12:30 Session 6: Implementing Optimal Practice

Session 6 How to use your Post-operative Histopathology Report:

Everything you want to know but are afraid to ask

Pembroke/Herbert

Chairs: Yvonne Summers (UK) and Jackie Fenemore (UK)

11:00	The pathologist's view	Siobhan Nicholson (IE)
11:15	The surgeon's view	John Edwards (UK)
11:30	The medical oncologist's view	Tanya Ahmad (UK)
11:45	The radiation oncologist's view	Rafal Dziadziuszko (PL)
12:00	Panel and audience discussion	

12:30 – 13:30 Lunch, Exhibition and Posters

**Ground Floor
Conference Foyer**

13:30 - 15:00 Session 7: UK Impact of Trial Data

Session 7

Pembroke/Herbert

Chairs: James Spicer (UK) and Lorraine Creech (UK)

Includes 5 minutes discussion per speaker

13:30	Radical treatment for oligometastatic NSCLC: should it be standard care?	Fiona McDonald (UK)
13:50	Can we treat mesothelioma cachexia?	Andrew Kidd (UK)
14:15	Will immunotherapy change outcomes in SCLC	Michaela Higgins (IE)
14:40	Nurse led systemic therapy delivery in immunotherapy era	Sandra Wakelin (UK)
15:00	Close	